Shots:

• EMA has granted orphan medicinal product designation for the treatment of patients with hepatocellular carcinoma (HCC)
• Orphan Medicinal Product designation provides regulatory and financial incentives for companies to develop and market therapies treating life-threatening or chronically debilitating condition affecting no more than 5 in 10-000 persons in the EU
• MIV-818 is a pro-drug designed to selectively treat liver cancer cells and has the potential to become the first liver-targeted- orally administered drug for patients with HCC

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Medivir